Skip to content Skip to footer
Subscribe Now
Disease of the Month: Duchenne Muscular Dystrophy (DMD)
INSIGHTS+
Disease of the Month: Duchenne Muscular Dystrophy (DMD)
INTRODUCTIONDuchenne Muscular Dystrophy (DMD) is a rare and the most frequent genetic neuromuscular disorder affecting all races and ethnicities (affecting approximately 1 in 3,500 population). It is characterized by progressive muscle weakness and some specific abnormalities like changes in muscle fiber size, scar tissue formation, muscle fiber necrosis, and inflammation evidenced from muscle biopsy…
September 29, 20220Comments
Viewpoints_Jay Pathmanathan
VIEWPOINTS
Jay Pathmanathan, Medical Director at Beacon Biosignals Shares Insights on EEG Neurobiomarkers for the Development of Precision Medicines in Neurology
Shots:Jay spoke about the role of AI-based EEG neurobiomarkers in the development of therapies to treat neurologic diseasesJay also talked about the use of the EEG analytics platform for dose determination clinical researchThe interview gives an understanding of Beacon Biosignals' vision to accelerate new treatment options for neurological and psychiatric diseasesSmriti: Throw…
September 27, 20220Comments
Viewpoints_Kindra Whitlatch
VIEWPOINTS
Kindra Whitlatch, Product Applications Manager at ThermoFisher Scientific, Shares Insights on Drug Stability Testing
Shots:Kindra talked about the stability testing process and its applications in the pharmaceutical industryShe also spoke about the different important parameters for stability testing and the challenges faced during this processThe interview gives a deep understanding of ThermoFisher is supporting pharmaceutical and biopharmaceutical manufacturers in the drug stability testing processSmriti: Please discuss…
September 26, 20220Comments
Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+
Top Performing Drug of 2021 – Eylea (September Edition)
Active Ingredient: AfliberceptStrength: 2 mg (0.05 mL)Dosage Form: Injection (intravitreal)Mechanism of Action: VEGF-A and PlGF inhibitorsFirst Approval: US (18 Nov 2011), EU (27 Nov 2012)Revenue1EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 20220Comments
Spotlight Interview_Rohan (Ro) F. Hastie
SPOTLIGHT
Spotlight Interview with Rohan (Ro) F. Hastie, President & CEO at Metabolon
PharmaShots had its third interview for the “Spotlight- Company of the Month- Metabolon’’. The interview was with Rohan (Ro) F. Hastie, President & CEO at Metabolon where he shared insights from the journey, products, solutions, technologies, and upcoming plans of Metabolon. Metabolon develops analytical methods and software for biomarker discovery by using metabolomics. The company…
September 22, 20220Comments
Viewpoints_Karl Bradshaw
VIEWPOINTS
Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre
Shots:Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 20220Comments
Viewpoints_Dr. Changjin Wang
VIEWPOINTS
Dr. Changjin Wang, CEO at Frontier Biotechnologies, Shares Insights on P-I Results of its Coronavirus Mpro Inhibitor
Shots:Changjin spoke about the P-I results of their lead candidate, Bofutrelvir to treat acute and long covid. The data was presented at the poster session of the 11th International Conference on ICEID, 2022Changjin also talked about the upcoming formulations of this innovative medicine and the initiation of its BRIGHT study covering the P-II/III…
September 19, 20220Comments